



International Journal of Advanced Biochemistry Research



ISSN Print: 2617-4693
ISSN Online: 2617-4707
NAAS Rating (2026): 5.29
IJABR 2026; SP-10(6): 1707-1710
www.biochemjournal.com
Received: 24-03-2026
Accepted: 26-04-2026

Dr. N Sudharani
Food Scientist, ICAR–Krishi
Vigyan Kendra (KVK),
Shivamogga, Karnataka, India

Dr. TN Dhanalakshmi
Breeder and Scheme Head,
AICRN on Tobacco, ZAHRS,
Shivamogga, Karnataka, India

Dr. MC Anjali
Assistant Professor,
Department of Soil Science,
College of Agriculture (CoA),
Mandya, Karnataka, India

Pharmacological profiles of *Bacopa monnieri*: A Comprehensive biochemical and therapeutic review

N Sudharani, TN Dhanalakshmi and MC Anjali

DOI: <https://www.doi.org/10.33545/26174693.2026.v10.i6St.8911>

Abstract

Bacopa monnieri (L.) Wettst. (Scrophulariaceae), popularly designated as "Brahmi," has been utilized for centuries in traditional medicine systems to enhance memory, intellect, and cognitive performance. This review provides a comprehensive analysis of the biochemical profile, molecular mechanisms, and pharmacological attributes of *B. monnieri*. The therapeutic efficacy of the plant is primarily driven by its unique steroidal saponins, specifically bacosides A and B. Biochemically, these compounds modulate critical neurotransmitter systems including cholinergic, monoaminergic, and gabaergic pathways while simultaneously upregulating endogenous antioxidant enzymes (superoxide dismutase, catalase, and glutathione peroxidase) to mitigate oxidative stress-induced neuronal apoptosis. Furthermore, recent molecular studies highlight its capacity to suppress pro-inflammatory cytokines via the NF- κ B pathway and diminish β -amyloid accumulation, positioning it as a viable therapeutic candidate for neurodegenerative pathologies such as Alzheimer's disease and Parkinson's disease. This article synthesizes the current state of clinical and preclinical research regarding the efficacy, safety, and molecular pharmacokinetics of *B. monnieri*.

Keywords: *Bacopa monnieri*, Bacosides, Neuroprotection, Synaptic plasticity, Acetylcholinesterase, Oxidative stress.

Introduction

Neurodegenerative disorders and age-associated cognitive decline present major global health challenges in the 21st century^[1]. Standard synthetic pharmaceuticals frequently fail to halt the progression of these multifaceted conditions and are routinely compromised by adverse systemic side effects. Consequently, identifying bioactive phytochemicals capable of multi-target therapeutic action has become a primary focus of biochemical and neuropharmacological research^[2].

Bacopa monnieri (L.) Wettst., a perennial, creeping succulent herb native to the wetlands of India, Asia, and the Americas, occupies a foundational role in Ayurvedic medicine as a *Medhya Rasayana* (a drug specialized in rejuvenating intellect and memory)^[3]. Over the past three decades, rigorous preclinical evaluation and clinical trials have validated its traditional indications. This review explores the structural chemistry of its primary isolates and delineates the precise molecular mechanisms by which *B. monnieri* exerts its neuroprotective, memory-enhancing, anxiolytic, and adaptogenic properties^[4].

2. Material and Methods

To evaluate the comprehensive biochemical and therapeutic profiles of *Bacopa monnieri*, a systematic literature mining process was conducted. Extensive electronic searches were performed across primary scientific databases, including PubMed, ScienceDirect, and Google Scholar, using specific indexing strings such as "*Bacopa monnieri*", "bacosides", "neuroprotection", and "biochemical mechanism"^[3, 4].

The inclusion criteria targeted peer-reviewed journal articles, experimental *in vivo* and *in vitro* models, and human clinical trials published up to 2026. Data extraction focused on isolating the primary chemical constituents, evaluating statistical indices of cognitive enhancement, tracking anti-inflammatory signalling cascades, and measuring changes in endogenous enzymatic antioxidants^[1, 5]. Information related to non-standardized mixtures or multi-herbal cocktails where individual plant efficacy could not be isolated was excluded from structural categorization.

Corresponding Author:
Dr. N Sudharani
Food Scientist, ICAR–Krishi
Vigyan Kendra (KVK),
Shivamogga, Karnataka, India

3. Results and discussion

The biochemical screening of *Bacopa monnieri* revealed a diverse chemical framework characterized by triterpenoid saponins, flavonoids, and sterols [3]. Bacoside A and bacoside B were identified as the primary therapeutic drivers responsible for modulating synaptic plastic responses [4, 5].

In experimental animal models subjected to neurotoxic stress, administration of the extract effectively altered neurotransmitter concentrations. Acetylcholine levels in the cerebral cortex rose significantly due to a measured deceleration of acetylcholinesterase activity [5]. Simultaneously, dopaminergic and gabaergic signaling structures were stabilized, which directly correlated with lowered behavioral deficits during learning paradigms [4]. Furthermore, biochemical assays demonstrated strong radical-scavenging metrics. The application of the isolated compound significantly increased the cellular expression of critical endogenous protective enzymes, including superoxide dismutase, catalase, and glutathione peroxidase [2]. This enzymatic upregulation successfully prevented lipid peroxidation within cellular membranes and halted downstream apoptotic programs within the CA1 hippocampal zones [2].

3.1 Botanical profile and phytochemical composition

The therapeutic matrix of *Bacopa monnieri* comprises an array of secondary metabolites. The primary bioactive components responsible for its clinical efficacy are steroidal saponins belonging to the dammarane class.

3.1. A Bacosides: The primary bioactive fraction

The complex saponin mixture structurally characterized as Bacoside A is identified as the major active component responsible for cognitive enhancement. Chromatographic and spectroscopic evaluations reveal that Bacoside A typically resolves into four distinct saponin congeners:

- Bacoside (A₃)
- Bacopaside II
- Bacopasaponin C
- The isomer of bacopaside I

Upon oral ingestion and subsequent enteric biotransformation, these saponins yield aglycones that readily cross the blood-brain barrier (BBB) to interact with localized neuronal targets.

3.1. B Secondary phytochemicals

Beyond core dammarane saponins, *B. monnieri* synthesizes several auxiliary compounds that contribute synergistically to its pharmacological profile:

- **Flavonoids:** Luteolin and apigenin, which provide intrinsic free-radical scavenging capacity.
- **Alkaloids:** Brahmine and herpestine, noted for mild neurological modulation.
- **Phytosterols:** Stigmasterol, (β)-sitosterol, and daucosterol, which aid in structural membrane stabilization.

3.2: Molecular mechanisms of action

3.2. A Modulation of neurotransmitter systems

B. monnieri acts as a systemic modulator of central neurotransmission rather than operating on a single receptor archetype:

- **The cholinergic system:** It systematically inhibits **Acetyl cholinesterase (ACHE)** activity in the frontal cortex and hippocampus. By preventing the enzymatic degradation of acetylcholine (ACH), it augments synaptic availability, thereby strengthening the foundational pathways required for memory encoding and retrieval.
- **The serotonergic system:** It upregulates the expression of tryptophan hydroxylase-2 (TPH2) and elevates serotonin transporter (SERT) density. This enhancement of serotonergic signaling helps account for its documented anxiolytic and mood-stabilizing effects.
- **GABAergic and glutamatergic equilibrium:** *B. monnieri* restores homeostasis between excitatory glutamate and inhibitory GABA signals. During states of hyperexcitability, it mitigates glutamate-mediated excitotoxicity by downregulating overactivated NMDA receptor subunits.

3.2. B Enhancement of synaptic plasticity and neurogenesis

At the structural level, chronic administration of *B. monnieri* induces morphological alterations in the central nervous system. It triggers a profound up-regulation of Brain-Derived Neurotrophic Factor (BDNF) and its cognate receptor, Tyrosine Kinase B (TrkB), within the hippocampal formations. This biochemical cascade accelerates:

1. Dendritic arborization (increased branching and length of dendrites).
2. Synaptic spine density optimization, directly reinforcing Long-Term Potentiation (LTP).

3.3 Mitigation of Oxidative Stress and Mitochondrial Dysfunction

The brain is uniquely susceptible to reactive oxygen species (ROS) due to its high oxygen consumption and high lipid content. *B. monnieri* exhibits powerful, direct metal-chelating and free-radical scavenging actions. At the gene-expression level, it stimulates the **Nrf2-ARE pathway**, inducing the transcription of endogenous antioxidant defenses:

$$\text{Nrf2 Activation} \rightarrow \uparrow \text{Superoxide Dismutase (SOD)} + \uparrow \text{Catalase (CAT)} + \uparrow \text{Glutathione Peroxidase (GPx)}$$

This multi-tiered defense prevents lipid peroxidation within neuronal membranes and preserves mitochondrial membrane potential ($\Delta\Psi_m$), preventing cytochrome *c* release and subsequent caspase-dependent apoptosis.

3.4. Pharmacological profiles and therapeutic indications

3.4. A. Nootropic and cognitive enhancement

Extensive human clinical trials demonstrate that *B. monnieri* significantly improves free recall, spatial learning, and information processing speed. Unlike synthetic stimulants (e.g., modafinil or methylphenidate), its cognitive effects are not instantaneous. Optimal benefits require a sustained regimen of 8 to 12 weeks, reflecting the time needed to manifest structural changes in dendritic growth and protein synthesis within the hippocampus.

Table 1: Comparative evaluation of human clinical trials utilising standardised extracts

Trial Setup	Intervention Profile	Timeline	Key Cognitive Parameters Measured
Double-Blind Placebo	300 mg daily extract	12 Weeks	Marked improvement in verbal learning and memory retention
Randomized Controlled	450 mg daily extract	8 Weeks	Significant acceleration in visual information processing rates
Open-Label Cohort	300 mg daily extract	16 Weeks	Decreased choice reaction times and reduced anxiety indices

Himani *et al.*, 2025.

3.4. B. Neuroprotection in dementia and alzheimer’s disease (AD)

The hallmark pathological features of Alzheimer's Disease involve the extracellular deposition of amyloid-beta ($A\beta$) plaques and intracellular neurofibrillary tangles (NFTs). *B. monnieri* counteracts these processes through multiple targeted actions:

- Plaque clearance:** It reduces $A\beta_{1-42}$ accumulation by enhancing endogenous clearance mechanisms and suppressing γ -secretase (BACE1) activity.
- Tau hyperphosphorylation:** It downregulates glycogen synthase kinase-3 β (GSK-3 β), an enzyme heavily implicated in abnormal tau protein hyperphosphorylation.

Table 2: Changes in biochemical parameters and neurological status across experimental groups

Groups	Change in bodyweight (unit)	Neurotransmitter Regulation	Antioxidant Activity
Control	Normal baseline	Stable homeostasis	Standard baseline
Negative control	Marked decline	Severe depletion	High oxidative stress
Protective	Minimal alteration	Maintained signaling	Elevated SOD and catalase
Curative	Gradual recovery	Gradual restoration	Restored baseline enzymes

3.4. C. Anxiolytic and Adaptogenic Activity

As a certified adaptogen, *B. monnieri* normalizes the physiological response to chronic stress. It modulates the Hypothalamic-Pituitary-Adrenal (HPA) axis by stabilizing serum corticosterone (or cortisol) spikes during acute duress. This action is accompanied by an increase in central dopamine and serotonin reserves, protecting against stress-induced depletion.

3.5. Pharmacokinetics and safety profile

- Absorption and bioavailability:** Hydrophilic bacosides exhibit relatively poor oral bioavailability in their native state. Modern formulation engineering including lipid-based nano-carriers and liposomal encapsulation is frequently deployed to enhance intestinal permeability.
- Metabolism:** Hepatic biotransformation cleaves the sugar moieties of the saponins, yielding active triterpenoid aglycones that easily penetrate the blood-brain barrier.

- Toxicity and Safety:** Animal toxicity evaluations indicate an extremely wide therapeutic index. Standard oral doses in humans (300–450 mg daily of standardized extract) are well-tolerated. Documented adverse reactions are mild and limited to gastrointestinal hypermotility, nausea, or abdominal cramping when consumed on an empty stomach. It does not display mutagenic, teratogenic, or hepatotoxic properties.

3.6. Chromatographic quantification of bacoside A

- The standard characterization and quality control of *Bacopa monnieri* extracts require precise High-Performance Liquid Chromatography (HPLC) coupled with Ultraviolet (UV) detection. Because individual bacosides share identical chromophores, they are quantified as a collective fraction under the following regulatory laboratory conditions:

Table 3: Chromatographic quantification of bacoside a

Parameter	Specification
Stationary Phase	C18 Reverse-Phase Column (250 x 4.6 mm, 5 μ m particle size)
Mobile Phase	Isocratic: Acetonitrile : 0.05 M Orthophosphoric acid (pH 3.0) in ratio 35:65 (v/v)
Flow Rate	1.0 mL / minute
Detection Wavelength	UV spectrophotometry at 205 nm
Injection Volume	20 μ L
Column Temperature	Maintained at 30°C

Discussion

the biochemical and therapeutic significance of *Bacopa monnieri* observed in contemporary studies aligns closely with its historic classification as a cognitive rejuvenator. The mechanical duality of the herb acting simultaneously as a neurotransmitter modulator and an antioxidant powerhouse gives it a distinct advantage over single-target synthetic molecules (1, 3). Comparative literature confirms that the elevation of endogenous antioxidant parameters helps counteract the chronic neuroinflammation driving Alzheimer's and

Parkinson's pathologies (1, 5). By inhibiting pro-inflammatory enzymes like cyclooxygenase-2 (COX-2) and restricting the mobilization of inflammatory cytokines, the plant protects delicate synaptic architectures from oxidative damage (2, 3). Furthermore, human clinical trials have increasingly verified these preclinical outcomes. Double-blind, placebo-controlled protocols demonstrated that standardized extracts generate notable enhancements in verbal learning, attention retention, and memory acquisition (4, 6). The localized upregulation of neurotrophic factors and the subsequent

improvement of cerebral blood flow provide a sound physical explanation for the observed cognitive benefits (5).

Conclusion and future perspectives

Bacopa monnieri represents a clinically validated phytotherapeutic agent capable of modulating complex, interconnected neuropathological pathways. Its multi-target mechanism spanning acetylcholinesterase inhibition, Nrf2-mediated antioxidant upregulation, BDNF induction, and anti-amyloidogenic activity distinguishes it from single-target synthetic alternatives. Future investigations should focus on large-scale, multi-center human clinical trials utilizing advanced standardized extracts with high bioavailability. Pinpointing the exact epigenetic modifications induced by chronic bacoside administration remains an open and promising frontier for molecular biochemistry.

References

1. Rastogi S, Pal R, Kulshreshtha DK. Bacoside A3: A new triterpenoid saponin from *Bacopa monnieri*. *Phytochemistry*. 1994;36(1):133-137.
2. Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S. Antioxidant activity of *Bacopa monnieri* congeners on mitochondrial systems. *Phytother Res*. 2000;14(2):102-108.
3. Stough C, Lloyd J, Clarke J, Downey LA, Hutchison CW, Rodgers T, Nathan PJ. The chronic effects of an extract of *Bacopa monnieri* (Brahmi) on human cognitive function. *Psychopharmacology (Berl)*. 2001;156(4):481-484.
4. Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B. Effects of a standardized *Bacopa monnieri* extract on cognitive performance, anxiety, and depression in the elderly. *J Altern Complement Med*. 2008;14(6):707-713.
5. Morgan A, Stevens J. Does *Bacopa monnieri* improve memory performance in older persons? A randomized, double-blind, placebo-controlled trial. *J Altern Complement Med*. 2010;16(7):753-759.
6. Aguiar S, Borowski T. Neuroprotective effects of *Bacopa monnieri* on ischemia-induced cell death. *Phytomedicine*. 2013;20(11):1033-1038.
7. Sumathi T, Nathiya S, Sakthikumar M. Protective effect of bacoside A on morphine-induced oxidative stress in rat brain regions. *J Histotechnol*. 2014;37(4):115-124.
8. Negi H, Patil A, Tubaki B, Kaundal S. Efficacy of Brahmaghrita in mild neurocognitive disorder: A randomized controlled trial. *Int J Ayurvedic Med*. 2025;16(2):514-524.